Two insiders at Adaptive Biotechnologies Corp. (ADPT) have recently divested a significant number of shares. On August 18, 2026, CEO and Chairman Chad M. Robins sold a total of 318,799 shares across two transactions, valued at approximately $8.00 million and $6.82 million respectively, at average prices of $25.08 and $24.48 per share.
These sales follow earlier transactions by another insider, Peter M. Neupert, who sold shares totaling over $3.13 million on August 17, 2026. In total, these recent insider dispositions amount to approximately $14.81 million.
While insider selling can be attributed to various personal financial strategies such as diversification or tax planning, the coordinated selling by multiple executives may attract investor attention. Adaptive Biotechnologies operates in the life sciences sector, focusing on immune medicine.